When illuminated, these "opsin" proteins change the flow of electrically charged ions within the cell, to help the cell turn light into energy or as a sensory cue.
In a talk last week, Clearwire laid out a hunker down strategy of not building too many more cell sites until its reimbursement negotiations with Sprint are ironed out and its cash flow improves.